CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma

Table 3 Univariate Cox regression for progression-free survival and overall survival (95% confidence interval)

Characteristic	PFS, HR	PFS, P value	OS, HR	OS, P value
CRAFITY (intermediate vs high)	0.48 (0.32-0.72)	< 0.001	0.35 (0.21-0.58)	< 0.001
CRAFITY (low vs high)	0.33 (0.21-0.54)	< 0.001	0.21 (0.11-0.4)	< 0.001
Sex (male vs female)	0.83 (0.55-1.24)	0.359	1.54 (0.82-2.9)	0.181
Age (≥ 60 years vs <60 years)	0.82 (0.6-1.13)	0.221	0.89 (0.59-1.36)	0.6
ECOG PS (1 vs 0)	0.94 (0.68-1.29)	0.688	1.32 (0.87-1.98)	0.191
Cirrhosis (present vs absent)	1.4 (0.89-2.2)	0.14	1.23 (0.67-2.26)	0.504
Resection (yes vs no)	0.68 (0.44-1.06)	0.093	0.86 (0.5-1.46)	0.568
TACE (yes vs no)	0.8 (0.51-1.27)	0.352	0.24 (0.14-0.41)	< 0.001
Ablation (yes vs no)	0.83 (0.61-1.14)	0.259	0.71 (0.47-1.09)	0.116
Treatment line (later vs first)	0.66 (0.45-0.96)	0.032	0.82 (0.52-1.31)	0.404
Number (≥ 3 vs < 3)	1.46 (1.06-2.02)	0.021	1.84 (1.16-2.91)	0.009
Size (≥ 5 cm vs < 5 cm)	1.21 (0.87-1.68)	0.247	1.19 (0.78-1.83)	0.417
PVTT (present vs absent)	1.34 (0.98-1.83)	0.064	1.4 (0.92-2.11)	0.114
EHM (present vs absent)	1.12 (0.82-1.53)	0.472	1.52 (1-2.31)	0.047
Child-Pugh grade (B vs A)	0.97 (0.7-1.35)	0.849	1.37 (0.91-2.08)	0.135
BCLC stage (C vs B)	0.98 (0.65-1.48)	0.933	0.75 (0.44-1.25)	0.265

PFS: Progression-free survival; HR: Hazard ratio; OS: Overall survival; ECOG PS: Eastern Cooperative Oncology Group performance status; TACE: Transarterial chemoembolization; PVTT: Portal vein tumor thrombosis; EHM: Extrahepatic metastasis; BCLC: Barcelona Clinic Liver Cancer.